Cronos Group Inc. (CRON) company profile
Close on Nov 13, 2026Market cap $1.25BP/E 19.9Yield –
About Cronos
Medicinal Chemicals & Botanical Products, SIC 2833
Cronos is a cannabinoid company that develops, produces, and markets cannabis products and intellectual property. The company operates through a single consolidated reporting segment covering its Canadian and Israeli operations. Its commercial brand portfolio includes Spinach, PEACE NATURALS, LIT, and Lord Jones. Product offerings encompass dried cannabis flower, pre-rolls, vaporizers, edibles, extracts, and tinctures for adult-use and medical applications. The company distributes products to provincial cannabis control authorities, private-sector retailers, and medical patients through pharmacy and third-party distribution channels.
The company maintains production, processing, and research facilities in Ontario, Canada, through Peace Naturals and Cronos GrowCo, alongside certified medical cultivation and manufacturing operations in Israel. Outside Canada and Israel, Cronos distributes branded and white-labeled medical cannabis products to international markets including Germany, the United Kingdom, Australia, Switzerland, and Malta. As of December 31, 2025, the company employed 610 full-time staff across Canada, the United States, and Israel. Principal executive offices are located in Stayner, Ontario, Canada.
Summary of the business section of Cronos's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Cronos Group Inc.
- Founded
- 2012
- Headquarters
- Stayner, A6
- Address
- 4491 Concession Rd 12 L0M 1S0
- Phone
- (416) 504-0004
- Website
- thecronosgroup.com
- Employees
- 610, Dec 31, 2025
- Industry
- Medicinal Chemicals & Botanical Products
- Incorporated in
- A1
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, Vaughan, Ontario, Canada
Stock & identifiers
- Ticker
- CRON
- Exchange
- Nasdaq
- IPO date
- Feb 27, 2018
- Shares outstanding
- 368M, Aug 3, 2026
- Public float
- $379.90M, Jun 30, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 1656472
- CUSIP
- 22717L101
- ISIN
- CA22717L1013
- FIGI
- BBG00D1PMS80
- Share class FIGI
- BBG006G267X6
- LEI
- 549300CWB04E8UOTWX71
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Michael Ryan Gorenstein | See remarks below, Director | 13,213,017 |
| Adam Wagner | See remarks | 124,229 |
| Christopher Martens | General Manager | – |
| Terrence Gregory Joseph Doucet | See Remarks | 110,588 |
| Shannon Buggy | See Remarks | 178,322 |
| Jared Matthew Kenost | See Remarks | 46,675 |
| Arye Weigensberg | See Remarks | 211,555 |
| Anna Shlimak | See Remarks | 358,595 |
| Jeffrey David Jacobson | Chief Growth Officer | 484,681 |
| Lloyd Anderson Wilson | VP, Controller | 10,500 |
| James Holm | Chief Financial Officer | 203,387 |
| James Andrew McGinness III | VP, Controller | 17,543 |
| James Daniel Rudyk | Director | 36,237 |
| Jason Marc Adler | Director | 10,657,451 |
| Murray R. Garnick | Director | 0 |
| Darren Chester Broughton | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $4.07M | $4.88M | $1.48M | $38 | $11 |
| FY2024 | $4.15M | $3.87M | $1.06M | $29 | $11 |
| FY2023 | $3.71M | $2.04M | $1.02M | $30 | $16 |
| FY2022 Gorenstein | $16.49M | $13.00M | $1.17M | $37 | $20 |
| FY2022 Kurt Schmidt | $727.99K | -$1.57M | $1.17M | $37 | $20 |
| FY2022 Michael Gorenstein | $16.49M | $13.00M | $1.17M | $37 | $20 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Michael Gorenstein Chairman, President and CEO | $775.00K | $174.38K | $1.94M | $1.18M | – | $4.07M | -2% |
| Anna Shlimak CFO | $356.02K | $34.83K | $427.80K | $394.13K | $10.50K | $1.22M | +45% |
| James Holm Former CFO (6) | $133.27K | $66.14K | – | $104.05K | $408.83K | $712.29K | -52% |
| Jeffrey Jacobson Chief Growth Officer | $323.06K | $53.67K | $371.52K | $378.64K | $10.50K | $1.14M | +1% |
| Shannon Buggy SVP, Global Head of People | $318.35K | $22.50K | $247.50K | $181.52K | $7.64K | $777.52K | +1% |
| Adam Wagner General Manager, Cronos Israel | $296.76K | $79.29K | $301.16K | $158.28K | $102.89K | $938.37K | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of December 31, 2025, Cronos had 610 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 15, 2026 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Apr 17, 2024 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Nov 23, 2021 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Nov 9, 2021 | Late filing | Notification of late filing |
| Mar 2, 2020 | Late filing | Notification of late filing |
| May 27, 2016 | Name change | Name changed from PharmaCan Capital Corp. to Cronos Group Inc. |
See a number that looks wrong?